Plant-based Biologics Market is expected to grow by US$ 24.9 Mn by 2027, progressing at a CAGR of 3.4% during the forecast period | Leaf Expression Systems, Zea Biosciences, Planet Biotechnology Inc., InVitria

Overview:

Plant-based biologics are drugs manufactured using plant molecular farming. They are also called as plant-made biologics. They have huge applications and advantages in traditional boundaries of vaccines and therapeutic proteins. For instance, recently it was proved that bacterial colicins which were derived from plants were proven to be effective as food additives in order to control pathogenic bacteria in food items. These colicins are very effective in fighting against strains of pathogenic Escherichia coli which causes food poisoning. Furthermore, it costs almost US$ 1.00 for producing one gram of purified colicins.

Global Plant-based Biologics Market is forecast to be valued at US$ 19.4 Mn in 2020 and is exhibited to exhibit a CAGR of 3.4% over the forecast period.

Click Here to Get a Sample Copy @ https://www.coherentmarketinsights.com/insight/request-sample/2394

Impact of COVID-19:

Many companies are carrying out several activities for supporting diagnostic centers and hospitals for battling COVID-19. Several companies have launched new products for combating COVID-19. For instance, iBio, Inc., declared that they have entered in an agreement with Planet Biotechnology Inc, in August 2020, for developing ACE2-Fc, Planet  Biotechnology’s COVID-19 therapeutic candidate.  This is a recombinant protein which consists of human angiotensin that converts enzyme 2 fused to a human immunoglobulin G Fc fragment. iBio is also developing various vaccine platforms using FastPharming plant-based production system in order to provide long-term immunity.

Rising number of clinical trials, products, partnerships and collaborations adopted by major players are estimated to boost growth of the global plant-based biologics market over the forecast period. For instance, Protalix Biotherapeutics has two major drug in the pipeline. OPRX-106 is a recombinant human tumor necrosis factor receptor II which has been plant cell-expressed and it has been fused to an IgG1 Fc domain in order to inhibit TNF alpha. This has been developed for oral administration and it is being used in the treatment of ulcerative colitis as the clinical trials in June 2018, have shown positive results.

Major players in the global plant-based biologics market are focusing on entering potential untapped markets in several regions by expansion of their manufacturing facilities. For instance, Ventria Bioscience Inc. expanded their laboratory and biomanufacturing facilities to Junction City, Kansas in 2017, for doubling their production capacity. This expanded facility has new additions like greenhouses, molecular biology lab, analytical lab, processing capacity and process development. Moreover, PlantForm Corporation and Axis Biotec Brasil collaborated to launch a joint venture which consisted of pilot production facility and a biopharmaceutical lab in 2017, in Rio de Janeiro.

Do You Have Specific Requirement? Ask To Our Experts: https://www.coherentmarketinsights.com/insight/talk-to-analyst/2394

Drivers:

Increasing adoption of inorganic growth strategies like partnerships and collaborations by key players is estimated to fuel growth of the global plant-based biologics market over t eh forecast period. For instance, iBio, Inc., declared that they have collaborated with CC-Pharming Ltd. in August 2019, for expanding their business. With this partnership iBio’s product rituximab royalty-bearing commercial license has for China has been given to CC-Pharming Ltd.

Key Takeaways:

• The plant-based biologics market is estimated to exhibit a CAGR of 3.4%over the forecast period, due to the rising product approvals and product launches by major players in the market.
• Glucocerebrosidase segment, among product type in the global plant-based biologics market is estimated to witness growth over the forecast period, due to rising product approvals for global plant-based biologics for human use. For instance, Pfizer Inc. and Protalix BioTherapeutics have declared that their taliglucerase alfa for injection has been approved by the U.S. Food and Drug Administration in May 2012. This is an enzyme replacement therapy used for adult patients suffering from type 1 Gaucher disease. This is the first drug developed by using ProCellEx, which is a plant-based biologics platform.

Key Players:

Key players active in the global plant-based biologics market are Byondis B.V., Leaf Expression Systems, Solarvest Bioenergy Inc., Zea Biosciences, Kentucky Bioprocessing, LLC, Planet Biotechnology Inc., Eleva GmbH, InVitria, Medicago Inc., PlantForm Corporation, Ventria Bioscience Inc., IBIO, Inc., Pfizer Inc. and Mapp Biopharmaceutical, Inc.

Buy This Complete Business Report @ https://www.coherentmarketinsights.com/insight/buy-now/2394

Reasons to buy this Plant-based Biologics Market Report

☑ It attempts an analysis of the competing scenario.

☑ The current and exceptional product revenue market.

☑ An in-depth data on the regional investigation and competitive landscape structure.

☑ It benefits in creating an awareness of the important key product segments.

☑ The marketing strategies, opportunities, and development factors are explained.

☑ Plant-based Biologics market size estimation and recent advancements in the industry are explained.

The Study Objectives are:

✔ A comprehensive insight into key players operating in the Plant-based Biologics Market and their corresponding data.
✔ It includes product portfolio, annual revenue, expenditure on research and development, geographical presence, key developments in recent years, and growth strategies.
✔ Regional analysis, which includes insight into the dominant market and corresponding market share.
✔ It also includes various socio-economic factors affecting the evolution of the market in the region.
✔ The report offers a comprehensive insight into different individuals from value chains such as raw materials suppliers, distributors, and stockholders.

Table of Content

Chapter 1 Industry Overview
1.1 Definition
1.2 Assumptions
1.3 Research Scope
1.4 Market Analysis by Regions
1.5 Plant-based Biologics Market Size Analysis from 2022 to 2028
11.6 COVID-19 Outbreak: Plant-based Biologics Industry Impact

Chapter 2 Global Plant-based Biologics Competition by Types, Applications, and Top Regions and Countries
2.1 Global Plant-based Biologics (Volume and Value) by Type
2.3 Global Plant-based Biologics (Volume and Value) by Regions

Chapter 3 Production Market Analysis
3.1 Global Production Market Analysis
3.2 Regional Production Market Analysis

Chapter 4 Global Plant-based Biologics Sales, Consumption, Export, Import by Regions (2017-2022)
Chapter 5 North America Plant-based Biologics Market Analysis
Chapter 6 East Asia Plant-based Biologics Market Analysis
Chapter 7 Europe Plant-based Biologics Market Analysis
Chapter 8 South Asia Plant-based Biologics Market Analysis
Chapter 9 Southeast Asia Plant-based Biologics Market Analysis
Chapter 10 Middle East Plant-based Biologics Market Analysis
Chapter 11 Africa Plant-based Biologics Market Analysis
Chapter 12 Oceania Plant-based Biologics Market Analysis
Chapter 13 South America Plant-based Biologics Market Analysis
Chapter 14 Company Profiles and Key Figures in Plant-based Biologics Business
Chapter 15 Global Plant-based Biologics Market Forecast (2022-2028)
Chapter 16 Conclusions
Research Methodology